The ruling requires all trials across the EU to be filed through the European Medicines Agency’s digital filing system.
If authorised, Vimkunya would be the first vaccine in the EU to protect adolescents aged 12 to 17 against Chikungunya.
The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.
The European Medicines Agency (EMA) said on Monday it would no longer post on X and would use rival Bluesky instead, becoming ...
Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...
Marketing authorization for the first EU vaccine to protect adolescents against chikungunya has been expedited for its public ...
A safety committee will review all evidence from trials and studies to shed more light on the potential risk of NAION.
Drug major Merck & Co. (MRK) announced Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use or ...
The global health landscape faces challenges and innovations, with the European review of Alzheimer's drug Leqembi, Ebola ...
Merck on Friday said the recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use covers the 21-valent conjugate vaccine for immunization for the prevention ...
Bristol Myers (BMY) announced the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has ...